Advanced search
Publication Cover
Expert Review of Proteomics Volume 10, 2013 - Issue 3
Submit an article Journal homepage
52
Views
5
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

Reverse-phase protein microarray highlights HER2 signaling activation in immunohistochemistry/FISH/HER2-negative breast cancers

Alessandra Tessitore Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, Via Vetoio, Coppito 2, 67100, L’Aquila, Italy. [email protected]
,
Francesca Zazzeroni Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, Via Vetoio, Coppito 2, 67100, L’Aquila, Italy. [email protected]
&
Edoardo Alesse Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, Via Vetoio, Coppito 2, 67100, L’Aquila, Italy. [email protected]
Pages 223-226 | Published online: 09 Jan 2014

References

  • The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61–70 (2012).
  • Spitale A, Mazzola P, Soldini D, Mazzucchelli L, Bordoni A. Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Ann. Oncol. 20(4), 628–635 (2009).
  • Slamon D, Eiermann W, Robert N et al.; Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med. 365(14), 1273–1283 (2011).
  • Awada A, Bozovic-Spasojevic I, Chow L. New therapies in HER2-positive breast cancer: a major step towards a cure of the disease? Cancer Treat. Rev. 38(5), 494–504 (2012).
  • Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N. Engl. J. Med. 358(13), 1409–1411 (2008).
  • Hofmann M, Stoss O, Gaiser T et al. Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy. J. Clin. Pathol. 61(1), 89–94 (2008).
  • Schmidt C. How do you tell whether a breast cancer is HER2 positive? Ongoing studies keep debate in high gear. J. Natl Cancer Inst. 103(2), 87–89 (2011).
  • Mueller C, Liotta LA, Espina V. Reverse phase protein microarrays advance to use in clinical trials. Mol. Oncol. 4(6), 461–481 (2010).
  • Awada A, Bozovic-Spasojevic I, Chow L. New therapies in HER2-positive breast cancer: a major step towards a cure of the disease? Cancer Treat. Rev. 38(5), 494–504 (2012).
  • Tuma RS. Cancer stem cell hypothesis and trastuzumab in HER2-negative tumors. J. Natl Cancer Inst. 104(13), 968–969 (2012).
  • Korkaya H, Paulson A, Iovino F, Wicha MS. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 27(47), 6120–6130 (2008).
  • Riley L, Zhou H, Lange K, Sinsheimer JS, Sehl ME. Determining duration of HER2-targeted therapy using stem cell extinction models. PLoS ONE 7(12), e46613 (2012).
  • Turashvili G, Leung S, Turbin D et al. Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situ hybridization (FISH): pathologist assessment compared to quantitative image analysis. BMC Cancer 9, 165 (2009).
  • Ciftlik AT, Lehr HA, Gijs MA. Microfluidic processor allows rapid HER2 immunohistochemistry of breast carcinomas and significantly reduces ambiguous (2+) read-outs. Proc. Natl Acad. Sci. USA 110(14), 5363–5368 (2013).
  • Wulfkuhle JD, Berg D, Wolff C et al. Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping. Clin. Cancer Res. 18(23), 6426–6435 (2012).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.